204 related articles for article (PubMed ID: 33603372)
1. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L
Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372
[TBL] [Abstract][Full Text] [Related]
2. Cellular Uptake and Transport Mechanism of 6-Mercaptopurine Nanomedicines for Enhanced Oral Bioavailability.
Zou Y; Gao W; Jin H; Mao C; Zhang Y; Wang X; Mei D; Zhao L
Int J Nanomedicine; 2023; 18():79-94. PubMed ID: 36636639
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
4. Glutathione-Sensitive Hyaluronic Acid-Mercaptopurine Prodrug Linked via Carbonyl Vinyl Sulfide: A Robust and CD44-Targeted Nanomedicine for Leukemia.
Qiu J; Cheng R; Zhang J; Sun H; Deng C; Meng F; Zhong Z
Biomacromolecules; 2017 Oct; 18(10):3207-3214. PubMed ID: 28835099
[TBL] [Abstract][Full Text] [Related]
5. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Riccardi R; Balis FM; Ferrara P; Lasorella A; Poplack DG; Mastrangelo R
Pediatr Hematol Oncol; 1986; 3(4):319-24. PubMed ID: 3153245
[TBL] [Abstract][Full Text] [Related]
6. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Kato Y; Matsushita T; Uchida H; Egi S; Yokoyama T; Mohri K
Eur J Clin Pharmacol; 1992; 42(6):619-22. PubMed ID: 1623901
[TBL] [Abstract][Full Text] [Related]
7. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Zuccaro P; Guandalini S; Pacifici R; Pichini S; Di Martino L; Guiducci M; Giuliano M; Di Tullio MT; Pettoello Mantovani M
Ther Drug Monit; 1991 Jan; 13(1):37-41. PubMed ID: 2057989
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia.
Lafolie P; Hayder S; Björk O; Peterson C
Eur J Clin Pharmacol; 1991; 40(6):599-601. PubMed ID: 1884741
[TBL] [Abstract][Full Text] [Related]
9. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability.
Lönnerholm G; Kreuger A; Lindström B; Myrdal U
Pediatr Hematol Oncol; 1989; 6(2):105-12. PubMed ID: 2702064
[TBL] [Abstract][Full Text] [Related]
10. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
Adam de Beaumais T; Jacqz-Aigrain E
Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
[TBL] [Abstract][Full Text] [Related]
12. Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.
Lafolie P; Björk O; Hayder S; Ahström L; Peterson C
Med Oncol Tumor Pharmacother; 1989; 6(4):259-65. PubMed ID: 2615529
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
16. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Lönnerholm G; Kreuger A; Lindström B; Ludvigsson J; Myrdal U
Pediatr Hematol Oncol; 1986; 3(1):27-35. PubMed ID: 3153216
[TBL] [Abstract][Full Text] [Related]
17. A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia.
Le TTT; Jost F; Raupach T; Zierk J; Rauh M; Suttorp M; Stanulla M; Metzler M; Sager S
Math Med Biol; 2019 Dec; 36(4):471-488. PubMed ID: 30357334
[TBL] [Abstract][Full Text] [Related]
18. Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.
Naushad SM; Dorababu P; Rupasree Y; Pavani A; Raghunadharao D; Hussain T; Alrokayan SA; Kutala VK
Cancer Chemother Pharmacol; 2019 May; 83(5):875-880. PubMed ID: 30806759
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent synergism and antagonism between methotrexate and 6-mercaptopurine in a human acute lymphoblastic cell line.
Kano Y; Akutsu M; Kasahara T; Sakamoto S
Eur J Cancer; 1991; 27(9):1141-5. PubMed ID: 1835625
[TBL] [Abstract][Full Text] [Related]
20. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia.
Adamson PC; Poplack DG; Balis FM
Leuk Res; 1994 Nov; 18(11):805-10. PubMed ID: 7967706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
